<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01472991</url>
  </required_header>
  <id_info>
    <org_study_id>TC-5619-238-CRD-004</org_study_id>
    <nct_id>NCT01472991</nct_id>
  </id_info>
  <brief_title>Safety &amp; Efficacy of TC-5619 in Adults With Inattentive-predominant Attention Deficit/Hyperactivity Disorder (ADHD)</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Fixed Dose Study to Assess Efficacy, Safety, and Tolerability of TC-5619 in Adults With Inattentive-Predominant Attention Deficit/Hyperactivity Disorder (ADHD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Targacept Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Targacept Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study is to assess if TC-5619 improves symptoms for adults diagnosed with the
      inattentive-predominant subtype of ADHD over a 4-week treatment period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A 3-arm, double-blind, randomized, placebo-controlled, multicenter, fixed dose study to
      assess efficacy and safety of TC-5619 in adults with inattentive-predominant attention
      deficit/hyperactivity disorder (ADHD) utilizing the Connor's Adult ADHD Rating
      Scale-Investigator Completed Version (CAARS-INV) inattentive subscale scores through 4 weeks
      of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inattentive Subscale of the Conner's Adult ADHD-Investigator Version (CAARS-INV)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Scores on the inattentive subscale of the CAARS-INV obtained at Day 1 (baseline) and weeks 2, 4, and 6. Primary comparison will be difference between Day 1 and Week 4 (TC-5619 5mg and 25 mg vs. placebo).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Conner's Adult ADHD-Investigator Version total score</measure>
    <time_frame>4 weeks</time_frame>
    <description>Scores on the total CAARS-INV obtained at Day 1 (baseline) and weeks 2, 4, and 6. Primary comparison will be difference between Day 1 and Week 4 (TC-5619 5mg and 25 mg vs. placebo).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conner's Adult ADHD Rating Scale-Subject Self-Rating Version (CAARS-S)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Scores on the CAARS-S obtained at Day 1 (baseline) and weeks 2, 4, and 6. Primary comparison will be difference between Day 1 and Week 4 (TC-5619 5mg and 25 mg vs. placebo).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">250</enrollment>
  <condition>Attention Deficit Hyperactivity Disorder</condition>
  <arm_group>
    <arm_group_label>TC-5619-238 (25mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TC-5619-238 25 mg will be provided as hard gelatin capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be provided as hard gelatin capsules similar to TC-5619-238</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TC-5619-238 (5 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TC-5619-238 5 mg will be provided as hard gelatin capsules.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TC-5619-238 5mg</intervention_name>
    <description>TC-5619-238 5mg capsule taken once daily for 4 weeks</description>
    <arm_group_label>TC-5619-238 (5 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TC-5619-238 25mg</intervention_name>
    <description>TC-5619-238 25mg capsules taken once daily for 4 weeks</description>
    <arm_group_label>TC-5619-238 (25mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules will be taken once daily for 4 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of Inattentive predominant ADHD per DSM-IV TR) criteria at Screening

          2. Score ≥ 2 on at least 6 of 9 items in the inattentive subscale of the CAARS-INV at
             Baseline (Day 1)

          3. Score of &lt; 2 on at least 4 of 9 items in the hyperactive/impulsivity subscale of the
             CAARS-INV at Baseline (Day 1)

          4. Score ≥ 4 (at least moderate) on the CGI-S

          5. Tobacco non-users as indicated by lack of tobacco use within the last 6 months prior
             to Screening, and by negative urinary cotinine level of &lt; 50 ng/mL after
             quantification

        Exclusion Criteria:

          1. Current DSM-IV Axis I psychiatric disorder other than ADHD;

          2. Use of tobacco cessation agents within 4 weeks prior to Screening

          3. Known or suspected drug abuse within the last 6 months prior to Screening

          4. Urine drug screen positive for illegal or non-prescribed drugs at Screening

          5. Patients at imminent risk of suicide or of danger to themselves or others as judged by
             the investigator

          6. Use of drugs affecting cognitive function within 4 weeks prior to Day 1. This includes
             use of any concomitant medications for treatment of ADHD.

          7. History of significant other major or unstable neurological, metabolic, hepatic,
             renal, hematological, pulmonary, cardiovascular (CV), gastrointestinal (GI), or
             urological disorder; or diagnosis of major depressive disorder

          8. Myocardial infarction within past year

          9. Seizure disorder within past year

         10. Type 1 diabetes mellitus (DM); type 2 DM that requires medication (diet-controlled
             allowed)

         11. HbA1C &gt; 7.4 at Screening

         12. BMI &lt; 15 or &gt; 35; male weight &lt; 100 lbs; female weight &lt; 80 lbs.

         13. Current tuberculosis (TB) or known systemic infection [Hepatitis B Virus (HBV),
             Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV)]

         14. Women of child-bearing potential and male participants unwilling or unable to use
             accepted methods of birth control

         15. Participation in another Central Nervous System (CNS)-related clinical trial in the
             last 3 months and any other clinical trial in last 30 days prior to Screening, or
             participation in a previous TC-5619 clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy Wilens, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Trials Network &amp; Institute, Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southwestern Research, Inc</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synergy Clinical Research Center</name>
      <address>
        <city>National City</city>
        <state>California</state>
        <zip>91920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MCB Clinical Research Centers, LLC</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Clinical Research Center, LLC</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc.</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Clinical Research Center, LLC</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc.</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compass Research, Inc.</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compass Research, LLC</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Network &amp; Institute, Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuro-Behavioral Clinical Reseach, Inc.</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Clinical Research Center</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CNS Healthcare</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FutureSearch Clinical Trials, LP</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2011</study_first_submitted>
  <study_first_submitted_qc>November 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2011</study_first_posted>
  <disposition_first_submitted>April 22, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>April 22, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 30, 2013</disposition_first_posted>
  <last_update_submitted>April 22, 2013</last_update_submitted>
  <last_update_submitted_qc>April 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ADHD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

